Attune Pharmaceuticals, Inc.
Records under this name other than patents Attune Pharmaceuticals, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 9 of 9 · Back to Attune Pharmaceuticals, Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,021,463 | Therapeutic inhibitory compounds Lapsed on the fee record Ended Jun 1, 2025 · From the USPTO record | Lapsed on the fee record | Ended Jun 1, 2025 | From the USPTO record |
| US 10,981,893 | Therapeutic inhibitory compounds Lapsed on the fee record Ended Apr 20, 2025 · From the USPTO record | Lapsed on the fee record | Ended Apr 20, 2025 | From the USPTO record |
| US 9,611,252 | Therapeutic inhibitory compounds Lapsed on the fee record Ended Apr 4, 2025 · From the USPTO record | Lapsed on the fee record | Ended Apr 4, 2025 | From the USPTO record |
| US 10,781,200 | Therapeutic inhibitory compounds Lapsed on the fee record Ended Sep 22, 2024 · From the USPTO record | Lapsed on the fee record | Ended Sep 22, 2024 | From the USPTO record |
| US 10,308,637 | Therapeutic inhibitory compounds Lapsed on the fee record Ended Jun 4, 2023 · From the USPTO record | Lapsed on the fee record | Ended Jun 4, 2023 | From the USPTO record |
| US 10,301,284 | Therapeutic inhibitory compounds Lapsed on the fee record Ended May 28, 2023 · From the USPTO record | Lapsed on the fee record | Ended May 28, 2023 | From the USPTO record |
| US 10,266,515 | Therapeutic inhibitory compounds Lapsed on the fee record Ended Apr 23, 2023 · From the USPTO record | Lapsed on the fee record | Ended Apr 23, 2023 | From the USPTO record |
| US 10,259,803 | Therapeutic inhibitory compounds Lapsed on the fee record Ended Apr 16, 2023 · From the USPTO record | Lapsed on the fee record | Ended Apr 16, 2023 | From the USPTO record |
| US 10,023,557 | Therapeutic inhibitory compounds Lapsed on the fee record Ended Jul 17, 2022 · From the USPTO record | Lapsed on the fee record | Ended Jul 17, 2022 | From the USPTO record |